New bladder cancer drug tested for safety in early trial
Disease control
Completed
This early-stage study tested the safety of a new drug called UGN-301 for people with recurring non-muscle invasive bladder cancer. The drug was delivered directly into the bladder, both by itself and combined with other treatments. The main goal was to find a safe dose and under…
Phase: PHASE1 • Sponsor: UroGen Pharma Ltd. • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC